Travere Therapeutics (TVTX) Cost of Revenue (2014 - 2026)

Travere Therapeutics (TVTX) has 13 years of Cost of Revenue data on file, last reported at $24.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 99.73% year-over-year to $24.8 million; the trailing twelve-month figure through Mar 2026 stood at $30.5 million (up 63.27% YoY), and the FY2025 full-year result was $10.3 million, up 33.51% from the prior year.
• Cost of Revenue for Q1 2026 stood at $24.8 million, up from $2.6 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $24.8 million in Q1 2026 and bottomed at $868000.0 in Q4 2022.
• The 5-year median for Cost of Revenue is $2.1 million (2022), against an average of $4.0 million.
• The widest annual swing landed in 2024, when Cost of Revenue tumbled 63.72%; it then soared 726.13% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $868000.0 in 2022, then soared by 425.81% to $4.6 million in 2023, then sank by 44.06% to $2.6 million in 2024, then changed by 0.0% to $2.6 million in 2025, then surged by 872.03% to $24.8 million in 2026.
• The last three Cost of Revenue figures came in at $24.8 million (Q1 2026), $2.6 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.

Peer Comparison